Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

These are the biggest dividend yields on the FTSE All Share Index as 2026 begins

Dr James Fox explains that large dividend yields can be a warning sign and investors need to look for signs…

Read more »

Investing Articles

Are BAE Systems shares the best UK industrials investment going into 2026?

Dr James Fox takes a closer look at BAE Systems shares and the alternatives following an impressive 2025 and as…

Read more »

Investing Articles

Is 2026 the year the Diageo share price bounces back?

Will next year be the start of a turnaround for the Diageo share price? Stephen Wright looks at a key…

Read more »

Investing Articles

Here’s my top FTSE 250 pick for 2026

UK investors looking for under-the-radar opportunities should check out the FTSE 250. And 2026 could be an exciting year for…

Read more »

Yellow number one sitting on blue background
Investing Articles

Here’s my number 1 passive income stock for 2026

Stephen Wright thinks a 5.5% dividend yield from a company with a strong competitive advantage is something passive income investors…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Should I sell my Scottish Mortgage shares in 2026?

After a strong run for Scottish Mortgage shares, our writer wonders if he should offload them to bank profits in…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Down 35%! These 2 blue-chips are 2025’s big losers. But are they the best shares to buy in 2026?

Harvey Jones reckons he's found two of the best shares to buy for the year ahead, but he also acknowledges…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

State Pension worries? 3 investment trusts to target a £2.6m retirement fund

Royston Wild isn't worried about possible State Pension changes. Here he identifies three investment trusts to target a multi-million-pound portfolio.

Read more »